These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 15899439)
21. Evaluation of topical cyclosporine for the treatment of dry eye disease. Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097 [TBL] [Abstract][Full Text] [Related]
22. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Hom MM Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135 [TBL] [Abstract][Full Text] [Related]
23. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Wilson SE; Perry HD Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588 [TBL] [Abstract][Full Text] [Related]
24. Successful tear lipid layer treatment for refractory dry eye in office workers by low-dose lipid application on the full-length eyelid margin. Goto E; Dogru M; Fukagawa K; Uchino M; Matsumoto Y; Saiki M; Tsubota K Am J Ophthalmol; 2006 Aug; 142(2):264-70. PubMed ID: 16876507 [TBL] [Abstract][Full Text] [Related]
25. Role of the tear film in the optical quality of the human eye. Montés-Micó R J Cataract Refract Surg; 2007 Sep; 33(9):1631-5. PubMed ID: 17720082 [TBL] [Abstract][Full Text] [Related]
26. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Gürdal C; Genç I; Saraç O; Gönül I; Takmaz T; Can I Curr Eye Res; 2010 Sep; 35(9):771-7. PubMed ID: 20795858 [TBL] [Abstract][Full Text] [Related]
27. Sodium hyaluronate eyedrops enhance tear film stability. Hamano T; Horimoto K; Lee M; Komemushi S Jpn J Ophthalmol; 1996; 40(1):62-5. PubMed ID: 8739501 [TBL] [Abstract][Full Text] [Related]
28. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Kim EC; Choi JS; Joo CK Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318 [TBL] [Abstract][Full Text] [Related]
29. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. Rao SN J Ocul Pharmacol Ther; 2010 Apr; 26(2):157-64. PubMed ID: 20415623 [TBL] [Abstract][Full Text] [Related]
30. [Topical cyclosporine for the treatment of ocular surface changes in contact lens wearers]. Egorova GB; Mitichkina TS; Fedorov AA; Shamsudinova AR Vestn Oftalmol; 2015; 131(1):36-42. PubMed ID: 25872385 [TBL] [Abstract][Full Text] [Related]
31. Clinical review: topical ophthalmic use of cyclosporin A. Utine CA; Stern M; Akpek EK Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287 [TBL] [Abstract][Full Text] [Related]
32. Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Yoon KC; Heo H; Im SK; You IC; Kim YH; Park YG Am J Ophthalmol; 2007 Jul; 144(1):86-92. PubMed ID: 17493572 [TBL] [Abstract][Full Text] [Related]
33. Dry eye symptoms following cataract surgery. Roberts CW; Elie ER Insight; 2007; 32(1):14-21; quiz 22-3. PubMed ID: 17533782 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121 [TBL] [Abstract][Full Text] [Related]
35. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Di Tommaso C; Valamanesh F; Miller F; Furrer P; Rodriguez-Aller M; Behar-Cohen F; Gurny R; Möller M Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2292-9. PubMed ID: 22427552 [TBL] [Abstract][Full Text] [Related]
36. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Trattler W; Katsev D; Kerney D Clin Ther; 2006 Nov; 28(11):1848-56. PubMed ID: 17213005 [TBL] [Abstract][Full Text] [Related]
37. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591 [TBL] [Abstract][Full Text] [Related]
38. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops. Gensheimer WG; Kleinman DM; Gonzalez MO; Sobti D; Cooper ER; Smits G; Loxley A; Mitchnick M; Aquavella JV J Ocul Pharmacol Ther; 2012 Oct; 28(5):473-8. PubMed ID: 22554205 [TBL] [Abstract][Full Text] [Related]
39. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye. Gehlsen U; Braun T; Notara M; Krösser S; Steven P Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781 [TBL] [Abstract][Full Text] [Related]
40. Restasis use in the chronic dry eye patient. Bataoel A Insight; 2007; 32(3):21. PubMed ID: 17953324 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]